United States· US:0049-0174_ce46d6b5-eab4-4630-8480-f13885be938e

Glucotrol

A glipizide product containing glipizide, registered in United States by Roerig. The same ATC class is registered in 8 of our 19 countries.

ATC A10BB07US label

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedGlucotrolATCA10BB07REGISTER NO.US:0049-0174_ce46d6b5…PACKS LISTED4CHECKEDJuly 19, 2026

Where it is registered

Glipizide is registered in 8 of 19 countries.

Countries holding a registration under ATC A10BB07 (glipizide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 7 of them publish a price we can compare per daily dose

Glipizide · ATC A10BB07

8 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Italyprice
  • Polandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of glipizide costs, country by country.

Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.056 in United States to $0.39 in France — a ×7.0 gap.

  • United States: $0.056 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Glipizide · price per daily dose (10 mg)

USD · FX 28 Sept 2026

  • FR France$0.39
  • IT Italy$0.32
  • US United States$0.056 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
GLIPIZIDE
Manufacturer
Roerig
Country
United States (US)
ATC code
A10BB07
ATC class
Glipizide
Defined daily dose
10 mg, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
July 19, 2026

Packs & prices · 4

  • ndc11
    0049017402
    100 TABLET, EXTENDED RELEASE in 1 BOTTLE (0049-0174-02)
  • ndc11
    0049017403
    500 TABLET, EXTENDED RELEASE in 1 BOTTLE (0049-0174-03)
  • ndc11
    0049-0174-02
  • ndc11
    0049-0174-03

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

745 interactions on record for glipizide.

Graded by severity as the source publishes them — 20 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Glipizide · interactions on record

745 records

  • 20 severe
  • 448 moderate
  • 51 minor
  • 226 info

Most severe, free to view

  • MiconazoleA07AC01severe
  • Magnesium carbonateA02AA01moderate
  • Magnesium oxideA02AA02moderate
  • Magnesium hydroxideA02AA04moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glipizide in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glipizide products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Czechia · Minidiab
  • Spain · Minodiab
  • France · Ozidia
  • United Kingdom (Northern Ireland) · Minodiab
  • Italy · Minidiab
  • Poland · Glipizide Bp Galena
  • Romania · Glucotrol Xl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/3c992039-a3d1-44cc-88d3-8713c88e1b67
GET /v1/drugs/3c992039-a3d1-44cc-88d3-8713c88e1b67?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "5",
  "substance": "GLIPIZIDE",
  "productndc": "0049-0174",
  "dosage_form": "TABLET, EXTENDED RELEASE",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "NDA020329",
  "marketing_category": "NDA"
}

See everything about glipizide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.